Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New interleukins: are there any more?

Massimo Gadina1, Paul R Ferguson, James A Johnston

  • 1Department of Microbiology and Immunology, School of Medicine, The Queen's University of Belfast, Belfast, Northern Ireland, UK. m.g.gadina@qub.ac.uk

Current Opinion in Infectious Diseases
|June 25, 2003
PubMed
Summary

Newly discovered interleukins, including the interleukin-12 family (interleukins 23 and 27) and interferon-lambdas (interleukins 28 and 29), are crucial for immune responses and offer new therapeutic avenues for various infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Evolving Landscape of JAK-STAT Inhibition in the Treatment of Immune Mediated Inflammatory Diseases.

The Journal of allergy and clinical immunology·2026
Same author

Type I Interferon Signature is Associated With Lung Disease, Drug-Associated Immune Reactions, and Genetic Variation in Interferon-Linked Pathways in Still Disease.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Type I interferon-mediated autoinflammation in two unrelated patients due to a proximal intronic splice site variant in <i>DNASE2</i>.

Research square·2025
Same author

Epigenetic dysregulation in aged muscle stem cells drives mesenchymal progenitor expansion via IL-6 and Spp1 signaling.

Nature aging·2025
Same author

Next generation sequencing analysis reveals complex genetic architecture of childhood-onset systemic lupus erythematosus.

Lupus science & medicine·2025
Same author

A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis.

Annals of the rheumatic diseases·2025

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Cytokines are essential regulators of the immune system, controlling processes like lymphoid development, differentiation, homeostasis, tolerance, and memory.
  • Type I cytokine receptors bind cytokines, including interferons (type II cytokine receptor family), which are vital for host defense.

Purpose of the Study:

  • To review newly discovered interleukins and their receptors.
  • To describe the interleukin-12 family (interleukins 23 and 27) and interferon-lambdas (interleukins 28 and 29).
  • To explore their structure, biological activities, and signaling pathways.

Main Methods:

  • Literature review of recent discoveries in cytokine research.
  • Analysis of the structural and functional characteristics of new interleukins and their receptors.

Related Experiment Videos

Main Results:

  • Discovery of new interleukins, expanding the interleukin-12 family with interleukins 23 and 27.
  • Identification of interleukins 28 and 29 (interferon-lambdas) that bind type II cytokine receptors.
  • Characterization of their structures, biological activities, and signaling mechanisms.

Conclusions:

  • These novel cytokines and receptors are key areas for future research.
  • Their discovery presents potential for new therapeutic strategies against intracellular and viral infections.